<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118513</article-id><article-id pub-id-type="publisher-id">ACM-44607</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_57447474.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胃癌与肠道菌群关系的研究进展
  Research Progress on the Relationship between Gastric Cancer and Intestinal Flora
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>瞳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>金煜</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青海省人民医院，青海 西宁</addr-line></aff><aff id="aff2"><addr-line>青海大学研究生院，青海 西宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3517</fpage><lpage>3522</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  近年来，随着众多高新科学技术的发展和应用，人们对消化系统的肿瘤有了长足的认知。大量的研究证明，肠道菌群的失衡和胃肠肿瘤的发生之间存在着错综复杂的关系。越来越多的研究表明，与正常人群相比，胃癌患者肠道菌群的含量及群落构成比例等各方面的差异不尽相同，胃癌患者的肠道微生物群落之间存在着丰度的转变。本文从胃癌与肠道菌群之间的关系，对二者之间的研究关系及进展作一相关综述，旨在为胃癌患者的预防、临床治疗及预后生存质量等有关方面提供一些新的思路及方法。
   In recent years, with the development and application of many high and new sciences and technologies, people have a considerable understanding of digestive system tumors. A large number of studies have proved that there is a complex relationship between the imbalance of intestinal flora and the occurrence of gastrointestinal tumors. More and more studies have shown that compared with the normal population, the content and composition of intestinal microflora in patients with gastric cancer are different. There is a change in the abundance of intestinal microflora in patients with gastric cancer. Based on the relationship between gastric cancer and intestinal flora, this paper reviewed the research relationship and progress between them, aiming to provide some new ideas and methods for the prevention, clinical treatment, prognosis and quality of life of gastric cancer patients.
 
</p></abstract><kwd-group><kwd>胃癌，肠道菌群，幽门螺杆菌, Gastric Cancer</kwd><kwd> Intestinal Flora</kwd><kwd> Helicobacter pylori</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>近年来，随着众多高新科学技术的发展和应用，人们对消化系统的肿瘤有了长足的认知。大量的研究证明，肠道菌群的失衡和胃肠肿瘤的发生之间存在着错综复杂的关系。越来越多的研究表明，与正常人群相比，胃癌患者肠道菌群的含量及群落构成比例等各方面的差异不尽相同，胃癌患者的肠道微生物群落之间存在着丰度的转变。本文从胃癌与肠道菌群之间的关系，对二者之间的研究关系及进展作一相关综述，旨在为胃癌患者的预防、临床治疗及预后生存质量等有关方面提供一些新的思路及方法。</p></sec><sec id="s2"><title>关键词</title><p>胃癌，肠道菌群，幽门螺杆菌</p></sec><sec id="s3"><title>Research Progress on the Relationship between Gastric Cancer and Intestinal Flora<sup> </sup></title><p>Tong Liu<sup>1*</sup>, Jinyu Yang<sup>2#</sup></p><p><sup>1</sup>Graduate School of Qinghai University, Xining Qinghai</p><p><sup>2</sup>Qinghai Provincial People’s Hospital, Xining Qinghai</p><p><img src="//html.hanspub.org/file/30-1572445x5_hanspub.png?20210818181238581" /></p><p>Received: Jul. 11<sup>th</sup>, 2021; accepted: Aug. 11<sup>th</sup>, 2021; published: Aug. 18<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/30-1572445x6_hanspub.png?20210818181238581" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>In recent years, with the development and application of many high and new sciences and technologies, people have a considerable understanding of digestive system tumors. A large number of studies have proved that there is a complex relationship between the imbalance of intestinal flora and the occurrence of gastrointestinal tumors. More and more studies have shown that compared with the normal population, the content and composition of intestinal microflora in patients with gastric cancer are different. There is a change in the abundance of intestinal microflora in patients with gastric cancer. Based on the relationship between gastric cancer and intestinal flora, this paper reviewed the research relationship and progress between them, aiming to provide some new ideas and methods for the prevention, clinical treatment, prognosis and quality of life of gastric cancer patients.</p><p>Keywords:Gastric Cancer, Intestinal Flora, Helicobacter pylori</p><disp-formula id="hanspub.44607-formula17"><graphic xlink:href="//html.hanspub.org/file/30-1572445x7_hanspub.png?20210818181238581"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/30-1572445x8_hanspub.png?20210818181238581" /> <img src="//html.hanspub.org/file/30-1572445x9_hanspub.png?20210818181238581" /></p></sec><sec id="s5"><title>1. 肠道菌群失调与胃癌的关系</title><p>近年来，随着人们生活习惯和周围环境的改变，众多常见肿瘤的发病率日渐提升。在消化系统肿瘤中，其中胃癌(Gastric Cancer, GC)占比较高，在世界排名中居于第四位 [<xref ref-type="bibr" rid="hanspub.44607-ref1">1</xref>]。目前，大多数学者认为GC的发病率及预后的发展等与幽门螺杆菌(Helicobacter pylori, HP)的感染、饮食习惯及方式、先天性遗传因素、胃部癌前病变、地方区域环境等多方面因素密切相关 [<xref ref-type="bibr" rid="hanspub.44607-ref2">2</xref>]。人类胃肠道中寄居着大量的微生物菌落，人体胃肠道微生态系统是机体最复杂的微生态系统之一，其原有健康模式下的相对动态平衡与人类身体的健康状态有着紧密的联系。当机体受到某些因素的干扰后，打破了机体内肠道菌群原有相对健康模式的动态平衡，将会导致宿主与菌群之间形成胃肠道微生态系统的失调紊乱 [<xref ref-type="bibr" rid="hanspub.44607-ref3">3</xref>]。一方面，肿瘤的进展可能通过尚未确定的机制来影响肠道微生物的组成；另一方面，肠道微生物群落也可以塑造肿瘤生存的微生物群和适宜生长的肿瘤微环境 [<xref ref-type="bibr" rid="hanspub.44607-ref4">4</xref>]。因此，全方面多角度研究肠道菌群的变化与GC之间发生发展的关系，在以后GC的早期检出率、临床的对症治疗和提高预后患者的生存质量等方面具有极其重要的意义。</p></sec><sec id="s6"><title>2. 肠道菌群及幽门螺杆菌对胃癌促成的影响</title><sec id="s6_1"><title>2.1. 幽门螺杆菌对GC促成的影响</title><p>HP是一种与GC发病密切相关且公认的致癌物 [<xref ref-type="bibr" rid="hanspub.44607-ref5">5</xref>]。HP属于革兰阴性菌的病原体，其与各种胃炎、胃及十二指肠溃疡、GC等息息相关相关。流行病学研究显示，全世界每一年新确诊的GC的病例当中，79%归因于HP的感染 [<xref ref-type="bibr" rid="hanspub.44607-ref6">6</xref>]。若胃黏膜持续不断的遭受HP的感染，可诱发炎症级联反应，从而进一步发展为萎缩性胃炎，这种情况会导致胃酸分泌能力下降使得其他通常在酸性环境下被杀死的微生物能够存活和增殖，从而极大的增加了GC发生的风险 [<xref ref-type="bibr" rid="hanspub.44607-ref7">7</xref>]。HP作为炎症的诱发因子的作用是显而易见的，然而并非遭受HP的感染就一定会引发GC，其还与所感染菌株的毒力的强弱、数量的多少、感染期的长短、宿主的生活习惯、先天性的遗传等各个方面密切相关。所以对于某些个体化高风险人群，及时及早根除HP，可以在一定程度上降低GC的发病率 [<xref ref-type="bibr" rid="hanspub.44607-ref8">8</xref>]。</p></sec><sec id="s6_2"><title>2.2. 肠道菌群的代谢产物对胃癌促成的影响</title><p>除了HP外，其他因素也有助于胃粘膜的持续炎症和胃癌的发展。胃肠道菌群可在某种微环境下产生一些特殊类型的毒素，并且通过一些通路来诱导其DNA分子使其损伤、增强炎症反应、拮抗肿瘤等机制，从而导致肠道菌群的紊乱进一步促进GC发生发展 [<xref ref-type="bibr" rid="hanspub.44607-ref9">9</xref>]。例如，肠道菌群可产生胆汁酸、多胺、短链脂肪酸等相关代谢产物，此类产物与GC的发生存在着千丝万缕的关系，接下来以此类代谢产物和GC之间的关系做进一步详细的阐述。</p><p>胆汁反流产生的胆汁酸是造成GC的高危因素之一，胆汁酸包括初级胆汁酸、次级胆汁酸等。次级胆汁酸主要通过JAK-STAT3、NF-κB信号分子通路的传导，从而促进GC细胞生长；然而并不是所有的胆汁酸都会参与促成GC的发生发展，有些类型的胆汁酸也会对GC的发生起到调控、抑制肿瘤发展的作用 [<xref ref-type="bibr" rid="hanspub.44607-ref10">10</xref>]。因此，通过使其分泌适量且所需特定类型的胆汁酸，以此来避免或降低GC的发生率。</p></sec></sec><sec id="s7"><title>3. 外力治疗干预措施对肠道菌群与胃癌的调节</title><sec id="s7_1"><title>3.1. 肠道菌群与微生态制剂</title><p>微生态制剂是将寄居在机体内正常微生物按照相关比例模仿机体内微生物群落的配比从而制成的微生物制剂，其制剂主要有益生元、益生菌、合生元等 [<xref ref-type="bibr" rid="hanspub.44607-ref11">11</xref>]。对于益生菌，一个被广泛接受的定义是“足够量的活的微生物培养后能给宿主带来益处的菌群” [<xref ref-type="bibr" rid="hanspub.44607-ref12">12</xref>]。目前虽然有一些证据能够表明益生菌可以用于对抗致癌物HP，但益生菌对于肠道菌群群落组成的影响以及是否可以抑制肿瘤形成仍然知之甚少。例如，多胺(腐胺等)在细胞增殖分裂的过程中必不可少。这些小胺在癌前病变组织中和肿瘤组织中都是维持细胞生长所必需的，而益生菌可能通过影响多胺的含量和功能来作为抗肿瘤药物 [<xref ref-type="bibr" rid="hanspub.44607-ref13">13</xref>]。</p></sec><sec id="s7_2"><title>3.2. 肠道菌群与抗生素及中药</title><p>抗生素可针对性的直接杀灭或抑制某些特殊细菌，胃肠道系统微生物群落以此来被调节。青霉素等抗生素被普遍用在治疗HP的感染，从而在病因起始阶段预防或避免GC的发生。另一方面，抗生素的滥用也可导致微生物群落的失调从而提高GC、食管癌等发生机率 [<xref ref-type="bibr" rid="hanspub.44607-ref14">14</xref>]。除此之外，通过机体消化系统微生物群落的一系列代谢和转换后，有些中药在抑制肿瘤发展的方面也起到了一定的效应。黄芩苷在微生物群落的微环境下经过一系列菌群的代谢后变成了黄芩素，后者可以起到抗肿瘤的作用 [<xref ref-type="bibr" rid="hanspub.44607-ref15">15</xref>]；姜黄素不仅可以维持肠道菌群的多样性，而且还能够发挥抗炎、抗氧化和抗肿瘤作用等相关作用 [<xref ref-type="bibr" rid="hanspub.44607-ref16">16</xref>]。不论是哪种治疗手段，抗生素亦或是中药，多多少少都会对GC胃肠道群落的相对动态平衡产生某些影响，也或是改善其免疫能力和肠粘膜屏障的作用，也或是其调节GC的治疗、发展及预后。总的来说，不论哪种治疗措施或者手段，大多都是在延迟着肿瘤的进展或者朝积极有利的方向发展，在一定程度上减轻了胃肠消化道肿瘤产生的不良反应及相关并发症，因此可以将其看作是一种关键的治疗措施。</p></sec><sec id="s7_3"><title>3.3. 免疫营养干预影响肠道微生态及胃肠肿瘤</title><p>对于一些个体化特殊的患者，尤其是免疫功能下降比较严重的，我们可以通过有选择性的、有目的性的添加或补充某些必须的营养物质以此来提高机体免疫力，也会对肠道微生态及胃肠肿瘤的预后及发展起到积极的调控。目前研究证据表明，免疫营养素如n-3多不饱和脂肪酸等在GC、溃疡等疾病中发挥调控的作用；同时，其也有助于减少在治疗GC化疗的过程中引起的肠道菌群紊乱，甚至与肿瘤预后及发展存在一定的相关性 [<xref ref-type="bibr" rid="hanspub.44607-ref17">17</xref>]。</p></sec><sec id="s7_4"><title>3.4. 联合化疗对围手术期免疫、炎症及肠道菌群的影响</title><p>联合化疗是进展期GC的主要治疗措施，化疗药物可以对机体的肿瘤细胞和健康细胞进行无差别、无分辨的杀伤，从而引发胃肠道群落的紊乱。例如，以小鼠作为实验对象进行顺铂的抗肿瘤治疗，其治疗效果不明显，然而将嗜酸乳杆菌与顺铂联合后，其抗肿瘤结果大幅度的好转，并且小鼠的生存率也得到了显著的提升 [<xref ref-type="bibr" rid="hanspub.44607-ref18">18</xref>]。所以当化疗联合特殊菌群共同治疗时，治疗效果的提高显而易见。因此，抗肿瘤药物与某些菌群的联合化疗在对肿瘤患者的治疗及预后的发展中是最佳的选择方式。</p><p>Miyata等 [<xref ref-type="bibr" rid="hanspub.44607-ref19">19</xref>] 研究还发现联合化疗在降低肿瘤细胞增殖、杀死更多肿瘤细胞、提高化疗效率方面有显著作用。GC患者联合化疗可明显缓解围手术期炎症反应，并且还提高了机体抵御外来物质入侵的能力，具有一定的临床应用价值 [<xref ref-type="bibr" rid="hanspub.44607-ref20">20</xref>]。</p></sec><sec id="s7_5"><title>3.5. 肠内营养和免疫治疗对肠道菌群参与的胃癌的影响</title><p>大多数GC患者多表现为消化系统的不适，如厌食、呕血、黑便、腹部不适等，因此相当一部分患者只能通过肠内营养的方式来维持生命体征。肠内营养制剂能在一定程度上刺激腹部脏器的血液循环，改善胃肠道黏膜的血流量，加速胃肠功能的恢复 [<xref ref-type="bibr" rid="hanspub.44607-ref21">21</xref>]。可能的原因是肠内营养液在成分及比例等各方面更加适合人体肠道菌群的模型，从而更加容易被小肠吸收利用；同时也抑制了肠道产生的内毒素进入到血液，在一定程度上肿瘤细胞的易位，减轻体内炎症反应程度，减少对相关血管的刺激，维持相对稳定的肠道菌群。免疫治疗在抗肿瘤的发展中也起到了举足轻重的作用。通过对肿瘤患者免疫检查点抑制剂精准的把控和利用，将肿瘤患者粪便当中的菌群进行合理科学的移植后，抗肿瘤的疗效会得到显著的升高 [<xref ref-type="bibr" rid="hanspub.44607-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.44607-ref23">23</xref>]。在此过程中，肠道菌群的稳定性及多样性在免疫治疗的的过程中也起到了至关重要的作用。</p></sec><sec id="s7_6"><title>3.6. 手术治疗通过肠道菌群来奏效</title><p>目前，在临床上，对于GC的手术治疗时机，大多数还是多选择在早期及进展期。新近的研究表明，手术治疗虽然对GC能够产生一定的疗效，然而这些治疗措施将会在一定程度上重新改变消化道的结构。此外，手术中麻药的应用也会不同程度地损害机体的免疫功能及其菌群结构 [<xref ref-type="bibr" rid="hanspub.44607-ref24">24</xref>]。手术治疗刺激肿瘤间质细胞产生的炎症因子会诱发体内血管生成和组织重构，例如il-10在一定程度上可以抑制机体对外来侵犯所产生的免疫能力，如肿瘤的入侵等，导致了免疫力的低下，进一步促进了肿瘤的恶化和发展 [<xref ref-type="bibr" rid="hanspub.44607-ref25">25</xref>]。因此，手术治疗可为营养不良或一般饮食难以满足营养需求的特殊患者提供免疫支持和提高预后生存率，此项措施具有一定的临床意义 [<xref ref-type="bibr" rid="hanspub.44607-ref26">26</xref>]。</p></sec></sec><sec id="s8"><title>4. 展望</title><p>随着医学的迅速发展，尽管近40年来GC的发病率和死亡率显著下降 [<xref ref-type="bibr" rid="hanspub.44607-ref27">27</xref>]，但GC在全球癌症死亡的排名中仍然处于第二大原因，GC在新诊断的肿瘤当中约占10% [<xref ref-type="bibr" rid="hanspub.44607-ref28">28</xref>]。GC严重影响着人类的生命健康，虽然引起GC的原因目前还不清晰，但近年来一些新兴的研究提出GC的发生在很大程度上被归因于肠道菌群的失调或紊乱 [<xref ref-type="bibr" rid="hanspub.44607-ref29">29</xref>]。本文通过对相关文献所报道的内容进一步阐述，归纳了GC与肠道菌群之间的相关性研究，了解了GC患者的肠道微生物群落丰富度和多样性可能诱发GC的一些危险因素及其目前众多的一些GC治疗措施对胃肠生物群落产生的一些影响，以此来通过这些菌群的改变或易位推测出其和GC的发生发展的关系。肠道微生态系统的相对平衡对机体的健康发展起着密不可分的作用，其中肠道菌群的作用在对抗肿瘤的过程当中也显得尤为突出，其功能或作用不仅可以拮抗体内某些原癌基因的激活和降解或清除致癌因子，而且还能够激发体内的某些抗肿瘤的菌群或因子 [<xref ref-type="bibr" rid="hanspub.44607-ref30">30</xref>]。</p><p>未来，我们需要通过更加科学合理的研究方法，多角度全方位地关注肠道菌群的变化，透彻清晰地了解GC与肠道菌群之间的起因和结果，并不只是局限于其相关性。届时，一方面我们可以通过准确地将粪菌当中的需要菌群进行合理科学的移植、有针对性地调节饮食习惯、对抗有害肠道代谢产物及细菌产物、细菌毒素等；另一方面，有针对性地监测符合这些标准的患者可以提高GC的早期发现的概率。GC的低生存率通常归因于晚期诊断 [<xref ref-type="bibr" rid="hanspub.44607-ref31">31</xref>]。因此，早期癌症检测的重要性在提高GC的整体生存率的过程中尤为重要。总之，这些肿瘤及抗肿瘤有关生物标志物的发现为GC患者的早期诊断、预测生存率或选择的治疗方法开辟了新的道路。本文探讨了胃肠道微生态系统与GC的相关性研究，旨在进一步更加清晰地揭示GC的发生发展机制，为今后临床上GC的治疗和预防奠定了一定的理论基础。</p></sec><sec id="s9"><title>文章引用</title><p>刘 瞳,杨金煜. 胃癌与肠道菌群关系的研究进展Research Progress on the Relationship between Gastric Cancer and Intestinal Flora[J]. 临床医学进展, 2021, 11(08): 3517-3522. https://doi.org/10.12677/ACM.2021.118513</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44607-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Moris, D., Schizas, D., Michalinos, A., et al. (2017) The Expression of Claudin-4 in Gastric Cancer Tissue: A Single Center Experience. Journal of BUON, 22, 403-409.</mixed-citation></ref><ref id="hanspub.44607-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Nikniaz, Z., Somi, M.H., Nagashi, S. and Nikniaz, L. (2017) Impact of Early Enteral Nutrition on Nutritional and Immu-nological Outcomes of Gastric Cancer Patients Under-Going Gastrostomy: A Systematic Review and Meta-Analysis. Nutrition and Cancer, 69, 693-701. &lt;br&gt;https://doi.org/10.1080/01635581.2017.1324996</mixed-citation></ref><ref id="hanspub.44607-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mayne, S.T., Risch, H.A., Dubrow, R., et al. (2001) Nutrient Intake and Risk of Subtypes of Esophageal and Gastric cancer. Cancer Epidemiology Biomarkers and Prevention, 10, 1055-1062.</mixed-citation></ref><ref id="hanspub.44607-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Matson, V. and Chervin, C.G. and Thomas, F. (2020) Cancer and the Microbiome: Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology, 160, 600-613. 
&lt;br&gt;https://doi.org/10.1053/j.gastro.2020.11.041</mixed-citation></ref><ref id="hanspub.44607-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bhandari, A. and Crowe, S.E. (2012) Helicobacter Pylori in Gastric Malignancies. Current Gastroenterology Reports, 14, 489-496. &lt;br&gt;https://doi.org/10.1007/s11894-012-0296-y</mixed-citation></ref><ref id="hanspub.44607-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Plummer, M., de Martel, C., Vignat, J., et al. (2016) Global Burden of Cancers Attributable to Infections in 2012: A Synthetic Analysis. Lancet Glob Health, 4, e609-e616. &lt;br&gt;https://doi.org/10.1016/S2214-109X(16)30143-7</mixed-citation></ref><ref id="hanspub.44607-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yu, G.Q., et al. (2017) Molecular Characterization of the Human Stomach Microbiota in Gastric Cancer Patients. Frontiers in Cellular and Infection Microbiology, 7, 302. &lt;br&gt;https://doi.org/10.3389/fcimb.2017.00302</mixed-citation></ref><ref id="hanspub.44607-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gao, J.-J., et al. (2018) Association between Gut Microbiota and Helicobacter Pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer. Frontiers in Cellular and Infection Microbiology, 8, 202. 
&lt;br&gt;https://doi.org/10.3389/fcimb.2018.00202</mixed-citation></ref><ref id="hanspub.44607-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Meng, C., Bai, C., Brown, T.D., et al. (2018) Human Gut Microbiota and Gastrointestinal Cancer. Genomic Proteomics Bioinformatics, 16, 33-49. &lt;br&gt;https://doi.org/10.1016/j.gpb.2017.06.002</mixed-citation></ref><ref id="hanspub.44607-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wan, Y., Yuan, J., Li, J., et al. (2020) Unconjugated and Secondary Bile Acid Profiles in Response to Higher-Fat, Lower-Carbohydrate Diet and Associated with Related Gut Microbiota: A 6-Month Randomized Controlled-Feeding Trial. Clinical Nutrition, 39, 395-404. &lt;br&gt;https://doi.org/10.1016/j.clnu.2019.02.037</mixed-citation></ref><ref id="hanspub.44607-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kuugbee, E.D., Shang, X., Gamallat, Y., et al. (2016) Structural Change in Microbiota by a Probiotic Cocktail Enhances the Gut Barrier and Reduces Cancer via TLR2 Signaling in a Rat Model of Colon Cancer. Digestive Diseases and Sciences, 61, 2908-2920. &lt;br&gt;https://doi.org/10.1007/s10620-016-4238-7</mixed-citation></ref><ref id="hanspub.44607-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Reid, G., Sanders, M.E., Gaskins, H.R., Gibson, G.R., Mercenier, A., Rastall, R., Roberfroid, M., Rowland, I., Cherbut, C. and Klaenhammer, T.R. (2003) New Scientific Paradigms for Probiotics and Prebiotics. Journal of Clinical Gastroenterology, 37, 105-118. &lt;br&gt;https://doi.org/10.1097/00004836-200308000-00004</mixed-citation></ref><ref id="hanspub.44607-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Francesco, R., Michele, L. and Antonella, O. (2014) Probiotics against Neoplastic Transformation of Gastric Mucosa: Effects on Cell Proliferation and Polyamine Metabolism. World Journal of Gastroenterology, 20, 13258-13272. 
&lt;br&gt;https://doi.org/10.3748/wjg.v20.i37.13258</mixed-citation></ref><ref id="hanspub.44607-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Boursi, B., Mamtani, R., Haynes, K., et al. (2015) Recurrent Antibiotic Exposure May Promote Cancer Formation-Another Step in Understanding the Role of the Human Microbiota? European Journal of Cancer, 51, 2655-2664.  
&lt;br&gt;https://doi.org/10.1016/j.ejca.2015.08.015</mixed-citation></ref><ref id="hanspub.44607-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C.Z., Zhang, C.F., Chen, L., et al. (2015) Colon Cancer Chemopreventive Effects of Baicalein, an Active Enteric Microbiome Metabolite from Baicalin. International Journal of Oncology, 47, 1749-1758.  
&lt;br&gt;https://doi.org/10.3892/ijo.2015.3173</mixed-citation></ref><ref id="hanspub.44607-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zam, W. (2018) Gut Microbiota as a Prospective Therapeutic Target for Curcumin: A Review of Mutual Influence. Journal of Nutrition and Metabolism, 2018, Article ID: 1367984. &lt;br&gt;https://doi.org/10.1155/2018/1367984</mixed-citation></ref><ref id="hanspub.44607-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">薛志刚. 免疫营养干预影响肠道微生态及胃肠肿瘤结局基础与临床初探[D]: [博士学位论文]. 北京: 北京协和医学院, 2020.</mixed-citation></ref><ref id="hanspub.44607-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Gui, Q.F., Lu, H.F., Zhang, C.X., et al. (2015) Well-Balanced Commensal Microbiota Contributes to Anti-Cancer Response in a Lung Cancer Mouse Model. Genetics and Molecular Research, 14, 5642-5651.  
&lt;br&gt;https://doi.org/10.4238/2015.May.25.16</mixed-citation></ref><ref id="hanspub.44607-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Miyata, H., Yano, M., Yasuda, T., et al. (2017) Randomized Study of the Clinical Effects of Omega-3 Fatty Acid-Containing Enteral Nutrition Support during Neoadjuvant Chemo-Therapy on Chemotherapy-Related Toxicity in Patients with Esophageal Cancer. Nutrition, 33, 204-210. &lt;br&gt;https://doi.org/10.1016/j.nut.2016.07.004</mixed-citation></ref><ref id="hanspub.44607-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zong, L., Li, H.Y. and Li, S.H. (2019) Effects of Neoadjuvant Chemotherapy Combined with Enteral Nutrition on Perioperative Immunity, Inflammation and Intestinal Flora in Gastric Cancer Patients. Official Journal of the Balkan Union of Oncology, 24, 1113-1119.</mixed-citation></ref><ref id="hanspub.44607-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Nakanoko, T., Kakeji, Y., Ando, K., et al. (2015) Assessment of Surgical Treatment and Postoperative Nutrition in Gastric Cancer Patients Older than 80 Years. Anticancer Research, 35, 511-515.</mixed-citation></ref><ref id="hanspub.44607-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Tinoco, R., Elmén, L., et al. (2019) Gut Microbiota Dependent Anti-Tumor Immunity Restricts Melanoma Growth in Rnf5-/-Mice. Nature Communications, 10, Article No. 1492. &lt;br&gt;https://doi.org/10.1038/s41467-019-09525-y</mixed-citation></ref><ref id="hanspub.44607-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Vétizou, M., Pitt, J.M., Daillère, R., et al. (2015) Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science, 350, 1079-1084. &lt;br&gt;https://doi.org/10.1126/science.aad1329</mixed-citation></ref><ref id="hanspub.44607-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Schinzari, G., Cassano, A., Orlandi, A., Basso, M. and Barone, C. (2014) Targeted Therapy in Advanced Gastric Carcinoma: The Future Is Beginning. Current Medicinal Chemistry, 21, 1026-1038.  
&lt;br&gt;https://doi.org/10.2174/0929867321666131129124054</mixed-citation></ref><ref id="hanspub.44607-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Park, D.J., Park, Y.S., Ahn, S.H. and Kim, H.H. (2017) Laparoscopic Proximal Gastrectomy as a Surgical Treatment for Upper Third Early Gastric Cancer. Korean Journal of Gastroenterology, 70, 134-140.</mixed-citation></ref><ref id="hanspub.44607-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Qiu, M., Zhou, Y.X., Jin, Y., et al. (2015) Nutrition Support Can Bring Survival Benefit to High Nutrition Risk Gastric Cancer Patients Who Received Chemotherapy. Support Care Cancer, 23, 1933-1939. 
&lt;br&gt;https://doi.org/10.1007/s00520-014-2523-6</mixed-citation></ref><ref id="hanspub.44607-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Coleman, M.P., Estève, J., Damiecki, P., Arslan, A. and Renard, H. (1993) Trends in Cancer Incidence and Mortality. IARC Scientific Publications, 121, 1-806.</mixed-citation></ref><ref id="hanspub.44607-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bornschein, J., Rokkas, T., Selgrad, M. and Malfertheiner, P. (2011) Gastric Cancer: Clinical Aspects, Epidemiology and Molecular Back-Ground. Helicobacter, 16, 45-52. &lt;br&gt;https://doi.org/10.1111/j.1523-5378.2011.00880.x</mixed-citation></ref><ref id="hanspub.44607-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Tlaskalová-Hogenová, H., Stěpánková, R., Kozáková, H., Hudcovic, T., Vannucci, L., Tučková, L., Rossmann, P., Hrnčíř, T., Kverka, M., Zákostelská, Z., Klimešová, K., Přibylová, J., Bártová, J., Sanchez, D., Fundová, P., Borovská, D., Srůtková, D., Zídek, Z., Schwarzer, M., Drastich, P. and Funda, D.P. (2011) The Role of Gut Micro-Biota (Commensal Bacteria) and the Mucosal Barrier in the Pathogenesis of Inflammatory and Autoimmune Diseases and Cancer: Contribution of Germ-Free and Gnotobiotic Animal Models of Human Diseases. Cellular &amp; Molecular Immunology, 8, 110-120. &lt;br&gt;https://doi.org/10.1038/cmi.2010.67</mixed-citation></ref><ref id="hanspub.44607-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">何力宏, 任龙飞, 吴永娜, 任程晖, 何咏霖, 张磊. 肠道菌群与胃肠肿瘤关系的研究进展[J]. 中国微生态学杂志, 2020, 32(10), 1215-1218, 1228.</mixed-citation></ref><ref id="hanspub.44607-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Nikniaz, Z., Somi, M.H., Nagashi, S. and Nikniaz, L. (2017) Impact of Early Enteral Nutrition on Nutritional and Immu-nological Outcomes of Gastric Cancer Patients Under-going Gastrostomy: A Systematic Review and Meta-Analysis. Nutrition and Cancer, 69, 693-701. &lt;br&gt;https://doi.org/10.1080/01635581.2017.1324996</mixed-citation></ref></ref-list></back></article>